Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – Research analysts at Cantor Fitzgerald upped their FY2017 EPS estimates for shares of Sunesis Pharmaceuticals in a research report issued on Tuesday. Cantor Fitzgerald analyst M. Goldstein now expects that the biopharmaceutical company will post earnings per share of ($1.94) for the year, up from their previous estimate of ($2.07). Cantor Fitzgerald has a “Hold” rating and a $3.00 price target on the stock. Cantor Fitzgerald also issued estimates for Sunesis Pharmaceuticals’ FY2018 earnings at ($1.96) EPS.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.35. During the same period in the prior year, the company posted ($0.12) earnings per share. TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at

Separately, Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 28th.

Shares of Sunesis Pharmaceuticals (SNSS) opened at 2.47 on Thursday. The company’s market cap is $58.08 million. The firm has a 50 day moving average price of $2.73 and a 200-day moving average price of $3.50. Sunesis Pharmaceuticals has a 12 month low of $2.41 and a 12 month high of $6.30.

Several large investors have recently bought and sold shares of the company. TFS Capital LLC bought a new stake in Sunesis Pharmaceuticals during the first quarter worth approximately $158,000. Renaissance Technologies LLC boosted its stake in Sunesis Pharmaceuticals by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 110,581 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 16,000 shares during the period. Finally, Neuberger Berman Group LLC boosted its stake in Sunesis Pharmaceuticals by 16.6% in the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 20,000 shares during the period. 55.15% of the stock is currently owned by institutional investors.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.